Applied Biosystems Announces Launch of ABI PRISM 3100-Avant Genetic Analyzer.Business Editors/Health & Medical Writers BIOWIRE2K FOSTER CITY, Calif.--(BW HealthWire)--March 4, 2002 Applied Biosystems Applied Biosystems, Inc. (formerly NASDAQ: ABIO) is the original name of a pioneer biotechnology company founded in 1981 in Foster City, California, among the Silicon Valley cities of the southern San Francisco Bay Area. Group (NYSE NYSE See: New York Stock Exchange :ABI Abi (ā`bī) [short for Abijah], in the Bible, King Hezekiah's mother. (Application Binary Interface) A specification for a specific hardware platform combined with the operating system. ), an Applera Corporation business, today announced the launch of the ABI PRISM(R) 3100-Avant Genetic Analyzer, another addition to the Applied Biosystems pioneering family of genetic analysis systems. The new system is expected to provide a new level of performance on a capillary-based system for life science researchers requiring low-to-medium throughput for DNA analysis DNA analysis Any technique used to analyze genes and DNA. See Chromosome walking, DNA fingerprinting, Footprinting, In situ hybridization, Jeffries' probe, Jumping libraries, PCR, RFLP analysis, Southern blot hybridization. . The system is expected to be used by researchers engaged in fields ranging from therapeutic discovery to food safety. The ABI PRISM(R) 3100-Avant Genetic Analyzer is a four capillary electrophoresis Capillary electrophoresis (CE), also known as capillary zone electrophoresis (CZE), can be used to separate ionic species by their charge and frictional forces. In traditional electrophoresis, electrically charged analytes move in a conductive liquid medium under the system that can be upgraded to the 16 capillary ABI PRISM(R) 3100 Genetic Analyzer. The upgrade allows low-to-medium throughput researchers to quadruple throughput as their laboratory needs expand. Similar to all of the Applied Biosystems genetic analysis systems, the 3100-Avant platform runs both ABI PRISM(R) BigDye(TM) Terminator chemistries for sequencing and five-dye chemistries for fragment analysis. The increased efficiency and sensitivity of the system reduces the amount of DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. required for each sample injection, which reduces the overall cost per sample. The 3100-Avant genetic analyzer supports a variety of applications including both de novo [Latin, Anew.] A second time; afresh. A trial or a hearing that is ordered by an appellate court that has reviewed the record of a hearing in a lower court and sent the matter back to the original court for a new trial, as if it had not been previously heard nor decided. and comparative sequencing, and genotyping. "The reference sequence of the human genome The human genome is the genome of Homo sapiens, which is composed of 24 distinct pairs of chromosomes (22 autosomal + X + Y) with a total of approximately 3 billion DNA base pairs containing an estimated 20,000–25,000 genes. has generated important structural information about genes and the genetic differences between individuals," said John S. West, vice president of DNA Platforms of Applied Biosystems. "The ABI PRISM(R) 3100-Avant Genetic Analyzer is expected to provide researchers with an additional tool to focus on the function of genes and how the genes are related to complex diseases, and a tool to discover and assay all types of mutations. Among Applied Biosystems' genotyping solutions, we believe the system is particularly well suited for analyzing areas of high mutation density often found in tumor suppressor genes tumor suppressor gene n. A gene that suppresses cellular proliferation. When inherited in a mutated state, it is associated with the development of various cancers, including most familial cancers. Also called antioncogene. and infectious agents, the types of SNP's often found in plants, and non-SNP mutations." The ABI PRISM(R) 3100-Avant Genetic Analyzer is a part of the Applied Biosystems line of capillary electrophoresis instruments for DNA analysis. The ABI PRISM(R) 310 Genetic Analyzer, the first commercial capillary sequencer See MIDI sequencer. (music) sequencer - Any system for recording and/or playback of music via a programmable memory which stores music not as audio data, but as some representation of notes. , was introduced in 1995 followed by the introduction of the 96-capillary ABI PRISM(R) 3700 DNA Analyzer system in 1999. Researchers engaged in the industrial-scale process of analyzing genomic information currently use the 3700 system worldwide. The 16 capillary ABI PRISM(R) 3100 Genetic Analyzer was introduced in April 2000, and was designed to provide the flexibility of the 310 genetic analyzer with the added throughput for medium-to-high throughput laboratories. The 3100 and 3100-Avant genetic analyzers were co-developed under a product development collaboration, which began 1997 between Applied Biosystems and Hitachi High-Technologies Corporation, an affiliate of Hitachi, Ltd., of Tokyo, Japan. All of Applied Biosystems capillary-based systems of instruments, reagents and software offer walk-away automation, robust operation and high sensitivity. Applied Biosystems electrophoresis systems serve a wide spectrum of researchers ranging from those working in small laboratories to those in production-scale genomics facilities. These systems are also used in non-research applications such as DNA typing and databasing in forensic laboratories. About Applera Corporation and Applied Biosystems Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids Nucleic acids The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits. (DNA and RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic ), small molecules, and proteins to make scientific discoveries, leading to the development of new pharmaceuticals, and to conduct standardized testing. Applied Biosystems is headquartered in Foster City, Calif., and reported sales of $1.6 billion during fiscal 2001. The Celera Genomics Group, headquartered in Rockville, Md., is engaged principally in integrating advanced technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera's businesses are its online information business and its therapeutics discovery business. The online information business is a leading provider of information based on the human genome and other biological and medical information. Through the therapeutic discovery business, Celera intends to leverage its genomic and proteomic capabilities to identify drug targets and diagnostic marker candidates, and to discover novel therapeutic candidates. Celera Diagnostics, a joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostics tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800/762-6923. Information about Applied Biosystems is available on the World Wide Web at www.appliedbiosystems.com. Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "expect" and "believe" among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 provides a "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to (1) rapidly changing technology and dependence on development of new products; (2) sales dependent on customers' capital spending capital spending Spending for long-term assets such as factories, equipment, machinery, and buildings that permits the production of more goods and services in future years. policies and government-sponsored research; (3) claims for patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. ; (4) and other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. Note to Editors: Applied Biosystems is a registered trademark and Applera, Celera, Celera Diagnostics and Celera Genomics are trademarks of Applera Corporation or its subsidiaries in the U.S. and certain other countries. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion